Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Regulating vaccines at the FDA...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Regulating vaccines at the FDA: development and licensure of Zika vaccines

Regulating vaccines at the FDA: development and licensure of Zika vaccines

Bibliographic Details
Main Authors: Marion F. Gruber, Philip R. Krause
Format: Article
Language:English
Published: Taylor & Francis Group 2017-06-01
Series:Expert Review of Vaccines
Subjects:
accelerated approval
animal rule
immune response
infectious disease
licensure pathways
surrogate marker
us fda
vaccine development
zika
vaccine approval process
Online Access:http://dx.doi.org/10.1080/14760584.2017.1324304
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://dx.doi.org/10.1080/14760584.2017.1324304

Similar Items

  • Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
    by: Mahnum Shahzad, et al.
    Published: (2024-12-01)
  • Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing Applications
    by: Abena S. Agyeman, et al.
    Published: (2022-02-01)
  • Drugs, Devices, and the FDA: Part 1
    by: Gail A. Van Norman, MD
    Published: (2016-04-01)
  • FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
    by: Cheryl Ho, et al.
    Published: (2022-01-01)
  • Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022Research in context
    by: Xingxian Luo, et al.
    Published: (2023-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs